Charnwood Molecular, a drug discovery CRO that specializes in enhancing the experience and success of complex drug discovery for clients globally, rebranded to Charnwood Discovery.

The rebranding reflects Charnwood Discovery’s evolution over the last 25 years into a partner for companies requiring standalone customized solutions though to fully integrated drug discovery. The company has experience and expertise in bioscience, ADME/DMPK and computer-aided drug design, in addition to discovery chemistry and chemical development services.

Lee Patterson, CEO said “We’re delighted to reveal our new name and identity which represents our purpose of contributing to improving the health and lives of people through complex drug discovery. Our commitment to delivering excellence and innovation in scientific research remains the same but with a name and brand that truly reflects this. We are excited about the possibilities this change will bring for both current and new customers.”